ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
위암 시장 규모는 향후 수년간 급성장이 전망됩니다. 2029년에는 연평균 성장률(CAGR) 13.9%로 62억 8,000만 달러로 성장합니다. 예측 기간 중의 성장은 전 세계 위암 발병률 증가, 공공 및 민간 의료비 지출 증가, 표적 치료제 및 생물제제 승인 급증, 제약사의 종양학에 대한 관심 증가, 연구기관과 바이오텍 기업과의 공동 연구 증가 등에 기인합니다. 이 기간 중 예상되는 주요 동향으로는 동반 진단의 통합, 임상 진료에 게놈 검사의 도입, 면역 치료 조합의 혁신, 내시경 기술의 발전, 미생물 기반 치료법 개발 등이 있습니다.
헬리코박터 파일로리균 감염의 유병률 증가는 향후 수년간 위암 시장의 성장을 촉진할 것으로 예측됩니다. 헬리코박터 파일로리균 감염은 헬리코박터 파일로리균이 위 점막에 정착해 염증과 궤양을 유발하고 위암의 위험을 높입니다. 이러한 감염률 증가는 주로 과밀하거나 비위생적인 생활환경에서 세균의 대변-구강 감염 및 구강 감염을 촉진하는 비위생적인 생활환경이 원인입니다. 헬리코박터 파일로리균은 위 점막의 만성 염증과 세포 손상을 유발하고 전암성 변화와 종양 형성을 유발하여 위암에 기여합니다. 예를 들어 2024년 11월 캐나다 정부는 2023년 헬리코박터 파일로리균 감염 재발률이 19%이며, 지역과 연령에 따라 차이가 있다고 보고한 바 있습니다. 이처럼 헬리코박터 파일로리 감염 유병률 증가는 위암 시장 확대에 박차를 가하고 있습니다.
위암 치료 시장의 주요 업체들은 HER2 음성 위 및 위식도 접합부(GEJ) 선암의 1차 치료를 개선하기 위해 클라우딘(CLDN18.2) 표적 세포 용해성 항체 요법과 같은 첨단 치료법 개발에 주력하고 있습니다. 이 치료법은 CLDN18.2를 발현하는 종양세포에 특이적으로 결합하도록 설계된 모노클로널 항체를 사용하며, 화학요법과 병용하여 세포독성 작용을 유도하여 무진행생존율과 전체생존율을 모두 향상시킵니다. 예를 들어 일본 제약사 아스텔라스제약 미국법인은 2024년 10월 클라우딘(CLDN18.2)을 표적으로 하는 세포 용해성 항체인 바이로이(zolbetuximab-clzb)를 위암 및 GEJ 암 치료제로 발표했습니다. 이 혁신적인 생물제제는 플루오로피리미딘 및 백금 기반 화학요법과 병행하여 정맥으로 투여되며, 임상시험에서 무진행 생존기간의 중앙값은 최대 10.6개월, 전체 생존기간은 최대 18.2개월로 나타났습니다. CLDN18.2 양성 암세포를 선택적으로 표적화하여 표적 외 독성을 줄이고 치료의 특이성을 높일 수 있으며, 진행성 위암에 대한 맞춤 종양학의 큰 진전입니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 위암 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 위암 시장 : 성장률 분석
세계의 위암 시장 실적 : 규모와 성장, 2019-2024
세계의 위암 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 위암 : TAM(Total Addressable Market)
제6장 시장 세분화
세계의 위암 시장 : 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
선암
림프종
위장관 기질 종양
카르시노이드 종양
기타 유형
세계의 위암 시장 : 치료 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
화학요법
표적치료
면역치료
방사선 치료
수술
세계의 위암 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
경구
비경구
세계의 위암 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원 약국
소매 약국
온라인 약국
세계의 위암 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
외래 수술 센터
병원과 전문 클리닉
기타 최종사용자
세계의 위암 시장 : 서브 세분화, 선암(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
장형
확산형
세계의 위암 시장 : 서브 세분화, 림프종(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
점막 관련 림프액 조직 림프종
미만성 거대 B세포 림프종
세계의 위암 시장 : 서브 세분화, 위장관 기질 종양(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
키트 양성 위장관 기질 종양
혈소판 유래 성장인자 수용체 α변이체 소화관 간질
야생형 위장관 기질 종양
세계의 위암 시장 : 서브 세분화, 카르시노이드 종양(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
전형적인 카르시노이드
비정형 카르시노이드
세계의 위암 시장 : 서브 세분화, 기타 유형(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
편평상피암
소세포암
미분화 종양
제7장 지역별·국가별 분석
세계의 위암 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 위암 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
위암 시장 : 경쟁 구도
위암 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
AstraZeneca plc
Novartis Ag
GlaxoSmithKline plc
Takeda Pharmaceutical Company Limited.
Eli Lilly And Company
Amgen Inc
Mayo Clinic
Daiichi Sankyo Company Limited.
Illumina Inc.
BeiGene Ltd.
Celltrion Healthcare Co. Ltd.
Biocon Limited.
Guardant Health Inc.
Zai Lab Limited.
MacroGenics Inc.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
위암 시장 2029 : 새로운 기회를 제공하는 국가
위암 시장 2029 : 새로운 기회를 제공하는 부문
위암 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁사 전략
제36장 부록
KSA
영문 목차
영문목차
Stomach cancer, also known as gastric cancer, is a disease characterized by the formation of malignant (cancerous) cells in the lining of the stomach. It originates in the mucus-producing cells of the stomach's inner layer and can spread to deeper layers and other parts of the body. Stomach cancer typically develops slowly and often shows no symptoms in its early stages, but as it progresses, symptoms such as indigestion, stomach pain, nausea, weight loss, and loss of appetite may occur.
The primary types of stomach cancer include adenocarcinoma, lymphoma, gastrointestinal stromal tumor, carcinoid tumor, and other variants. Adenocarcinoma is a type of cancer that develops in the glandular cells lining certain internal organs and is commonly found in the stomach, lungs, prostate, and colon. Treatment options encompass chemotherapy, targeted therapy, immunotherapy, radiation therapy, and surgical procedures, administered via various routes such as oral and parenteral. Distribution occurs through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies, serving a range of end users like hospitals, specialty clinics, ambulatory surgery centers, and others.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The stomach cancer market research report is one of a series of new reports from The Business Research Company that provides stomach cancer market statistics, including stomach cancer global market size, regional shares, competitors with stomach cancer market share, detailed stomach cancer market segments, market trends and opportunities, and any further data you may need to thrive in the stomach cancer industry. The stomach cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The stomach cancer market size has grown rapidly in recent years. It will grow from $3.27 billion in 2024 to $3.74 billion in 2025 at a compound annual growth rate (CAGR) of 14.1%. The growth observed during the historic period can be attributed to the increasing prevalence of Helicobacter pylori infection, advancements in targeted therapy development, greater use of combination chemotherapy regimens, rising availability of immunotherapy treatments, and shifting lifestyle patterns.
The stomach cancer market size is expected to see rapid growth in the next few years. It will grow to $6.28 billion in 2029 at a compound annual growth rate (CAGR) of 13.9%. The growth during the forecast period can be attributed to a rise in global stomach cancer incidence rates, increased public and private healthcare spending, a surge in approvals of targeted therapies and biologics, growing interest from pharmaceutical companies in oncology, and an increase in collaborations between research institutions and biotech firms. Major trends expected in this period include the integration of companion diagnostics, incorporation of genomic testing in clinical practice, innovations in immunotherapy combinations, advancements in endoscopic techniques, and the development of microbiome-based therapies.
The increasing prevalence of Helicobacter pylori infection is anticipated to drive the growth of the stomach cancer market in the coming years. Helicobacter pylori infection occurs when the bacteria Helicobacter pylori colonize the stomach lining, causing inflammation, ulcers, and elevating the risk of stomach cancer. This rise in infection rates is mainly attributed to poor sanitation, which promotes fecal-oral and oral-oral transmission of the bacteria in overcrowded or unsanitary living environments. Helicobacter pylori contributes to stomach cancer by inducing chronic inflammation and cellular damage in the stomach lining, leading to precancerous changes and tumor formation. For example, in November 2024, the Government of Canada reported that the recurrence rate of Helicobacter pylori infection was 19% in 2023, with variations depending on geographic location and age. Thus, the growing prevalence of Helicobacter pylori infection is fueling the expansion of the stomach cancer market.
Key players in the stomach cancer treatment market are focusing on developing advanced therapies such as claudin (CLDN18.2)-targeted cytolytic antibody therapy to improve first-line treatment for HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinoma. This therapy uses a monoclonal antibody designed to specifically bind to tumor cells expressing CLDN18.2 and trigger cytotoxic effects when combined with chemotherapy, enhancing both progression-free and overall survival rates. For instance, in October 2024, Astellas Pharma US, Inc., a Japan-based pharmaceutical firm, introduced Vyloy (zolbetuximab-clzb), a claudin (CLDN18.2)-targeted cytolytic antibody for treating gastric and GEJ cancers. Administered intravenously alongside fluoropyrimidine- and platinum-based chemotherapy, this innovative biologic demonstrated median progression-free survival of up to 10.6 months and overall survival of up to 18.2 months in clinical trials. By selectively targeting CLDN18.2-positive cancer cells, it reduces off-target toxicity and enhances treatment specificity, representing a major advancement in personalized oncology for advanced gastric cancer.
In February 2025, GSK plc., a UK-based pharmaceutical company, acquired IDRx, Inc. for $1.15 billion. With this acquisition, GSK aims to bolster its oncology pipeline by advancing innovative targeted therapies for cancer treatment. IDRx, Inc., a US-based biopharmaceutical company, specializes in the discovery and development of precision oncology treatments that target specific genetic mutations in cancer.
Major players in the stomach cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck And Co. Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Novartis Ag, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited., Eli Lilly And Company, Amgen Inc, Mayo Clinic, Daiichi Sankyo Company Limited., Illumina Inc., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited., Guardant Health Inc., Zai Lab Limited., MacroGenics Inc.
North America was the largest region in the stomach cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in stomach cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the stomach cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The stomach cancer market consists of revenues earned by entities by providing services such as diagnostic services, surgical services, post-treatment monitoring and palliative care, genetic and biomarker testing, and clinical trial services. The market value includes the value of related goods sold by the service provider or included within the service offering. The stomach cancer market also includes sales of diagnostic tools and kits, surgical instruments and devices, companion diagnostics, supportive care medications, and biomarker testing kits. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Stomach Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on stomach cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for stomach cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The stomach cancer market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Adenocarcinoma; Lymphoma; Gastrointestinal Stromal Tumor; Carcinoid Tumor; Other Types
2) By Therapy Type: Chemotherapy; Targeted Therapy; Immunotherapy; Radiation Therapy; Surgery
3) By Route of Administration: Oral; Parenteral
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-User: Ambulatory Surgery Centers; Hospitals And Specialty Clinics; Other End-Users
Subsegments:
1) By Adenocarcinoma: Intestinal Type; Diffuse Type
2) By Lymphoma: Mucosa-Associated Lymphoid Tissue Lymphoma; Diffuse Large B-Cell Lymphoma
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Stomach Cancer Market Characteristics
3. Stomach Cancer Market Trends And Strategies
4. Stomach Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Stomach Cancer Growth Analysis And Strategic Analysis Framework
5.1. Global Stomach Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Stomach Cancer Market Growth Rate Analysis
5.4. Global Stomach Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Stomach Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Stomach Cancer Total Addressable Market (TAM)
6. Stomach Cancer Market Segmentation
6.1. Global Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adenocarcinoma
Lymphoma
Gastrointestinal Stromal Tumor
Carcinoid Tumor
Other Types
6.2. Global Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Targeted Therapy
Immunotherapy
Radiation Therapy
Surgery
6.3. Global Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
6.4. Global Stomach Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Stomach Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ambulatory Surgery Centers
Hospitals And Specialty Clinics
Other End-Users
6.6. Global Stomach Cancer Market, Sub-Segmentation Of Adenocarcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intestinal Type
Diffuse Type
6.7. Global Stomach Cancer Market, Sub-Segmentation Of Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mucosa-Associated Lymphoid Tissue Lymphoma
Diffuse Large B-Cell Lymphoma
6.8. Global Stomach Cancer Market, Sub-Segmentation Of Gastrointestinal Stromal Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
